Page last updated: 2024-11-04

guanidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Guanidine is a colorless, hygroscopic, crystalline organic compound with the formula (NH2)2C=NH. It is a strong base and readily absorbs water from the air. It is also a highly reactive molecule and can be used to synthesize a variety of important compounds. Guanidine is an important component of several biologically active molecules, including arginine and creatine. It is also used in the synthesis of polymers, explosives, and pharmaceuticals. Guanidine can be synthesized from various sources, including urea, ammonia, and calcium cyanamide. The synthesis of guanidine involves the reaction of urea with ammonia in the presence of a catalyst, such as a metal oxide. Guanidine is an important compound because of its diverse biological and industrial applications. It is a key component of several important biological molecules, such as arginine and creatine. Guanidine is also used in the synthesis of polymers, explosives, and pharmaceuticals. Guanidine is studied extensively because of its important role in biology and chemistry. Researchers are interested in understanding the properties of guanidine and its role in various biological and chemical processes. This includes its role in protein folding, enzyme activity, and drug development. The study of guanidine is important for understanding the fundamentals of chemical and biological processes and for developing new technologies in medicine, materials science, and other fields.'

Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

guanidine : An aminocarboxamidine, the parent compound of the guanidines. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3520
CHEMBL ID821
CHEBI ID42820
MeSH IDM0029365

Synonyms (46)

Synonym
AKOS009031425
carbamamidine
brn 0506044
einecs 204-021-8
aminoformamidine
guanidine
GAI ,
guanidine, hydrochloride
carbamidine
CHEBI:42820 ,
guanidin
h2n-c(=nh)-nh2
iminourea
113-00-8
gu
aminomethanamidine
imidourea
DB00536
NCIOPEN2_007946
A9B89FF5-2922-47CC-82CE-AC4157B624AE
CHEMBL821
unii-ju58vj6y3b
4-03-00-00148 (beilstein handbook reference)
hsdb 7603
ju58vj6y3b ,
guanidine, free base
C17349
STL223269
bdbm50420178
FT-0626820
guanidine [mi]
guanidine [vandf]
guanidine [hsdb]
guanidine [who-dd]
EPITOPE ID:140101
gtpl4783
(nh2)2c=nh
90332-86-8
AB00053583_04
DTXSID0023117
SBI-0207070.P001
GZ6 ,
Q183309
ribavirin impurity t; iminourea;diaminomethanimine;guanidinebase;carbamidine
BCP26146
CS-0440981

Research Excerpts

Overview

Guanidine prenylation is an outstanding modification in alkaloid and peptide biosynthesis, but its enzymatic basis has remained elusive. The guanidine-I riboswitch is a conserved RNA element with approximately 2,000 known examples across four phyla of bacteria.

ExcerptReferenceRelevance
"Guanidine prenylation is an outstanding modification in alkaloid and peptide biosynthesis, but its enzymatic basis has remained elusive. "( Argicyclamides A-C Unveil Enzymatic Basis for Guanidine Bis-prenylation.
Balloo, N; Fujita, K; Matsuda, K; Okino, T; Phan, CS; Wakimoto, T, 2021
)
2.32
"The guanidine-I riboswitch is a conserved RNA element with approximately 2,000 known examples across four phyla of bacteria. "( Structural Basis for Ligand Binding to the Guanidine-I Riboswitch.
Reiss, CW; Strobel, SA; Xiong, Y, 2017
)
1.28
"Guanidine is an active ingredient extracted from Galega officinalis. "( Activation of imidazoline I(2B) receptors by guanidine to increase glucose uptake in skeletal muscle of rats.
Chang, CH; Cheng, JT; Huang, SY; Tsao, CW, 2009
)
2.06
"The guanidine molecule is a main structural unit in these complexes, while the studied acids have similar chemical character."( New complexes of guanidine with acetic, trichloroacetic and trifluoroacetic acids. The DFT structural and vibrational investigations.
Drozd, M, 2008
)
1.17
"Guanidine hydrochloride acts as a classical electrolyte in the reversible suppression of charge effects, and not as a denaturing or dissociation agent."( Polyelectrolyte behaviour in mucus glycoproteins.
Creeth, JM; Harding, SE, 1983
)
0.99
"Guanidine is a weak competitive inhibitor of the L-arginine-dependent effector mechanism."( L-arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells.
Hibbs, JB; Taintor, RR; Vavrin, Z, 1987
)
0.99

Effects

Guanidine has the highest basicity among many common functional groups in nature. Guanidine has been shown to potentiate neurotransmission at the skeletal neuromuscular junction. It increases acetylcholine release at nerve terminals through K, Na and Ca channels.

ExcerptReferenceRelevance
"Guanidine has the highest basicity among many common functional groups in nature."( Synthesis and evaluation of a deltic guanidinium analogue of a cyclic RGD peptide.
Fukui, M; Kinuya, S; Mishiro, K; Ogawa, K; Ueno, T; Wakabayashi, H, 2023
)
1.63
"Guanidine has been used with some success to treat myasthenia gravis and myasthenic syndrome because it increases acetylcholine release at nerve terminals through K⁺, Na⁺ and Ca²⁺ channels-involving mechanisms. "( Guanidine affects differentially the twitch response of diaphragm, extensor digitorum longus and soleus nerve-muscle preparations of mice.
da Cruz Höfling, MA; Ferrari, R; Rodrigues-Simioni, L, 2012
)
3.26
"Guanidine has been shown to potentiate neurotransmission at the skeletal neuromuscular junction. "( Influence of extracellular calcium on the actions of guanidine at the rat neuromuscular junction.
Badia, A; Baños, JE; Bosch, F; Morales, M,
)
1.82

Actions

ExcerptReferenceRelevance
"Guanidine was shown to cause blueshifts in the BL spectra and stimulate the activity of the red-emitting luciferases (from lambda max = 623 to lambda max = 600 nm) and in PxGr R215S (from lambda max = 585 to lambda max = 560 nm) mutant luciferase, but not in the green-emitting luciferases, suggesting that guanidine can simulate positively charged residues involved in BL color determination."( Bioluminescence color determinants of Phrixothrix railroad-worm luciferases: chimeric luciferases, site-directed mutagenesis of Arg 215 and guanidine effect.
Ohmiya, Y; Viviani, VR, 2000
)
1.23

Treatment

Guanidine hydrochloride (GuHCl) was used to treat neuromuscular disease. The patient died of refractory leukemia. Guanidine HCl or heat treatment of NGF resulted in only small, but significant, changes in binding or biological activity.

ExcerptReferenceRelevance
"Guanidine-treated rhIFNβ-1a mostly consisted of dimers and oligomers and some non-covalent aggregates smaller in size than those in untreated rhIFNβ-1a."( Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.
Brinks, V; Gilli, F; Jiskoot, W; Sauerborn, M; Schellekens, H; van Beers, MM, 2011
)
1.09
"Guanidine treatment released two phage proteins (P3 and P5)."( Structure of the lipid-containing bacteriophage PRD1: disruption of wild-type and nonsense mutant phage particles with guanidine hydrochloride.
Bamford, D; Mindich, L, 1982
)
1.19
"Guanidine treatment at pH 4.5 decreased the reversible stabilities of Gly137-->Ala, Gly139-->Ala and Gly137/Gly139-->Ala/Ala glucoamylases at infinite dilution while not changing those of Gly251-->Ala and Gly383-->Ala glucoamylases, which is, in general, opposite to what occurred with thermoinactivation."( Effect of replacing helical glycine residues with alanines on reversible and irreversible stability and production of Aspergillus awamori glucoamylase.
Buehler, FU; Chen, HM; Ford, C; Li, Y; Panda, T; Reilly, PJ, 1996
)
1.02
"Guanidine HCl or heat treatment of NGF resulted in only small, but significant, changes in binding or biological activity, in parallel with changes in recognition by the MAbs."( Characterization of ultra-high affinity monoclonal antibodies with a dimeric, symmetrical antigen: inhibition of the receptor recognition site of nerve growth factor.
Buxser, SE; Crumm, E; Vroegop, SM, 1992
)
1
"Upon treatment with guanidine hydrochloride (GuHCl), a 1.8 THz peak appeared for CP47 and free chlorophyll a (Chl a)."( The guanidine hydrochloride-induced denaturation of CP43 and CP47 studied by terahertz time-domain spectroscopy.
Chen, H; Kuang, T; Li, L; Qin, X; Qu, Y; Wang, L, 2007
)
1.21
"Treatment with guanidine hydrochloride resulted in clinical improvement of the neuromuscular disease, but the patient died of refractory leukemia."( Eaton-Lambert syndrome in a patient with acute T cell lymphocytic leukemia.
Clinton, ME; Manian, FA; Morrow, JD; Stein, RS, 1988
)
0.61

Toxicity

Guanidine therapy is relatively safe and effective for long-term symptomatic treatment of LEMS when it is combined with pyridostigmine. Guanidine is also toxic to yeast.

ExcerptReferenceRelevance
" The compounds tested were selected to fulfill two molecular criteria underlying the toxic activity of 1-methyl-4-phenylpyridinium (MPP+), the active metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toward dopaminergic cells: 1) to be a substrate for the selective uptake system of the dopaminergic neurons and 2) to possess a delocalized positive charge related to their ability to inhibit mitochondrial electron transport."( Toxic effects of potential environmental neurotoxins related to 1-methyl-4-phenylpyridinium on cultured rat dopaminergic neurons.
Dandapani, BK; Efange, S; Hefti, F; Michel, PP; Pressman, BC; Sanchez-Ramos, J, 1989
)
0.28
" Thus, we conclude that low-dose guanidine therapy is relatively safe and effective for long-term symptomatic treatment of LEMS when it is combined with pyridostigmine."( Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome.
Claussen, GC; Head, TC; Kim, DS; Oh, SJ, 1997
)
1
"Studies were conducted using a novel in vitro approach to investigate the efficacy of acetamidine hydrochloride (ACE) and guanidine hydrochloride (GUAN), previously shown to block gramicidin D (GRAM) channels in artificial membranes, in preventing the toxic effects of GRAM in NG108-15 (neuroblastoma x glioma hybrid) cells."( Gramicidin toxicity in NG108-15 cells: protective effects of acetamidine and guanidine.
Doebler, JA, 1999
)
0.74
" Patients were evaluated at regular intervals for adverse events."( The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction.
Benevides, M; Carson, CC; Linnet, O; Parivar, K; Patel, M; Vick, RN, 2002
)
0.31
" No serious adverse events or cardiovascular effects were noted."( The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction.
Benevides, M; Carson, CC; Linnet, O; Parivar, K; Patel, M; Vick, RN, 2002
)
0.31
" PNU-83757 was efficacious and extremely well tolerated, and the only adverse events were mild."( The efficacy, safety and tolerability of intracavernous PNU-83757 for the treatment of erectile dysfunction.
Benevides, M; Carson, CC; Linnet, O; Parivar, K; Patel, M; Vick, RN, 2002
)
0.31
" Guanidine is also toxic to yeast, irrespective of the status of Hsp104 and [PSI+]."( Deletion of the Hsp70 chaperone gene SSB causes hypersensitivity to guanidine toxicity and curing of the [PSI+] prion by increasing guanidine uptake in yeast.
Jones, GW; Masison, DC; Song, Y, 2003
)
1.46
" In what respects the effect of the different cations, it is possible to recognize that the phosphonium-based ILs seem to be more toxic when compared to the analog imidazolium-based ILs (with the same anion and alkyl chains)."( Toxicity assessment of various ionic liquid families towards Vibrio fischeri marine bacteria.
Afonso, CA; Coutinho, JA; Gonçalves, F; Marques, CS; Rosatella, AA; Ventura, SP, 2012
)
0.38
" Here we utilize a model based on glutamine stretches of 0, 30 or 56 residues in Saccharomyces cerevisiae to understand how such toxic proteins interfere with cellular physiology."( A network of genes connects polyglutamine toxicity to ploidy control in yeast.
Eckl, JM; Grötzinger, SW; Jordan, S; Kaiser, CJ; Papsdorf, K; Richter, K, 2013
)
0.39
" AT3 variants carrying the expanded polyQ are prone to associate with each other into amyloid toxic aggregates, which are responsible for neuronal death with ensuing neurodegeneration."( The Toxic Effects of Pathogenic Ataxin-3 Variants in a Yeast Cellular Model.
Bonanomi, M; Invernizzi, G; Regonesi, ME; Tortora, P; Visentin, C, 2015
)
0.42
" For individual reagents, PHMG-H was found to be more toxic than BEC in terms of both mortality and genotoxicity."( Toxicity of benzethonium chloride and polyhexamethylene guanidine hydrochloride mixtures on Daphnia carinata: synergistic and antagonistic effects at specific ratios.
Cao, Q; Lu, Y; Wang, L; Wang, Y; Wei, W; Yang, H; Yang, T; Zhang, F; Zhang, Y, 2023
)
1.16

Pharmacokinetics

ExcerptReferenceRelevance
" Similar results were obtained by measuring PAI-1 activity in plasma and with trace amounts of 125I-rPAI-1, suggesting that the above pharmacokinetic behavior could also apply to endogenous PAI-1."( The pharmacokinetics of plasminogen activator inhibitor-1 in the rabbit.
Fujita, T; Gardell, SJ; Mayer, EJ; Reilly, CF; Shebuski, RJ, 1990
)
0.28
"The pharmacokinetic parameters of guanidine hydrochloride were analysed in dogs with an hereditary neuromuscular transmission disorder by the use of 14C-guanidine hydrochloride."( Pharmacokinetics and pharmacodynamics of guanidine hydrochloride in an hereditary myasthenia gravis-like disorder in dogs.
Flagstad, A; Nielsen, P; Trojaborg, W, 1986
)
0.82

Compound-Compound Interactions

ExcerptReferenceRelevance
" This work presents the first description of CB6 in combination with a new guanidinium-based ionic liquid (GBIL) as the GC stationary phase by using sol-gel coating method for the preparation of the CB6-GBIL and GBIL columns."( Cucurbit[6]uril in combination with guanidinium ionic liquid as a new type of stationary phase for capillary gas chromatography.
Fu, R; Qi, M; Wang, L; Wang, X, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" Both BW 467C60 and BW 392C60 were well absorbed from the alimentary tract."( Adrenergic neurone blockade and other acute effects caused by N-benzyl-N'N"-dimethylguanidine and its ortho-chloro derivative.
BOURA, AL; GREEN, AF, 1963
)
0.47
" However, its oral bioavailability in humans proved to be below acceptable limits."( Exploration of potential prodrugs of RWJ-445167, an oxyguanidine-based dual inhibitor of thrombin and factor Xa.
Costanzo, MJ; Damiano, BP; Giardino, EC; Lu, T; Maryanoff, BE; McComsey, DF; Player, MR; Yabut, SC, 2006
)
0.58
" The oral bioavailability was rabbit >rat> monkey compared at 100 mg/kg, but it was much higher in dogs (>64%) after oral administrations."( Pharmacokinetic properties of TDP4815 after single intravenous and oral administrations to rat, rabbit, monkey, dog and in vitro drug metabolism.
Bone, R; Chen, Y; Cheng, D; Dasgupta, M; Eisennagel, S; Huebert, N; Kagan, N; Tio, C; Tomczuk, B, 2008
)
0.35
"N1-Aryl(heteroaryl)alkyl-N2-[3-(1H-imidazol-4-yl)propyl]guanidines are potent histamine H2-receptor (H2R) agonists, but their applicability is compromised by the lack of oral bioavailability and CNS penetration."( Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.
Bernhardt, G; Buschauer, A; Dove, S; Elz, S; Ghorai, P; Götte, C; Igel, P; Keller, M; Kraus, A; Schneider, E; Schnell, D; Seifert, R; Zabel, M, 2008
)
1.15
" Both compounds had low bioavailability and may be recommended for further investigations as excipients to be externally applied."( Polysulfones of new structural types as perspective antioxidant agents.
Anikina, L; Gorbunova, M, 2013
)
0.39
" Thus, thiophene-diguanidino derivatives with improved bioavailability when administered orally could lead to treatment options against AE."( In vitro and in vivo activities of dicationic diguanidino compounds against Echinococcus multilocularis metacestodes.
Boykin, DW; Hemphill, A; Kriegel, N; Küster, T; Stephens, CE, 2013
)
0.39
"Determining the bioavailability of lysine in foods and feedstuffs is important since lysine is often the first limiting indispensable amino acid in diets for intensively farmed livestock (pigs and poultry) and also in many cereal-based diets consumed by humans."( Use of the guanidination reaction for determining reactive lysine, bioavailable lysine and gut endogenous lysine.
Rutherfurd, SM, 2015
)
0.42
"Water-soluble prodrug strategy is a practical alternative for improving the drug bioavailability of sparingly-soluble drugs with reduced drug efficacy."( Novel prodrugs with a spontaneous cleavable guanidine moiety.
Hamada, Y, 2016
)
0.7
" However, the bioavailability of IBG is not optimal due to its finite aqueous solubility, thus hampering its potential therapeutic exploitation."( Enhancement of the oral bioavailability of isopropoxy benzene guanidine though complexation with hydroxypropyl-β-cyclodextrin.
Lu, Y; Peng, X; Qin, Z; Xie, S; Yang, L; Zeng, D; Zeng, Z; Zhang, W; Zhao, F, 2022
)
0.96

Dosage Studied

ExcerptRelevanceReference
" Dose-response studies with the lambda lacZ mice indicated a threshold for mutation induction in stem cells at low ENU dosages, which is in accordance with the specific-locus test data."( Germ cell mutagenesis in lambda lacZ transgenic mice treated with ethylnitrosourea; comparison with specific-locus test.
Baan, RA; van Delft, JH, 1995
)
0.29
" A significant improvement in tumor growth inhibition was observed after dosing with LPD-PEG-AA containing DSGLA."( Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells.
Bathula, SR; Chen, Y; Fittipaldi, R; Huang, L; Sen, J; Yang, Q,
)
0.13
" Surprisingly, a nonlinear dose-response with an activity threshold around 3-4 μM, indicative of large cooperativity, was observed."( Cellular Antisense Activity of PNA-Oligo(bicycloguanidinium) Conjugates Forming Self-Assembled Nanoaggregates.
de Mendoza, J; Nielsen, PE; Shiraishi, T; Valero, J, 2015
)
0.42
" Clinical studies of SI showed promising benefits on mild to moderate AD, however, with limitations on dosage regime."( A guanidine-appended scyllo-inositol derivative AAD-66 enhances brain delivery and ameliorates Alzheimer's phenotypes.
Chung, SK; Das, S; Jung, HY; Kim, KT; Kim, YK; Lee, D; Lee, J; Lee, WS; Lim, S; Luo, W, 2017
)
1.18
" Median effective dose was interpolated from the triplicated experiments and the dose-response curves were generated for each drug-virus combination."( A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses.
Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
carboxamidineCompounds having the structure RC(=NR)NR2. The term is used as a suffix in systematic nomenclature to denote the -C(=NH)NH2 group including its carbon atom.
one-carbon compoundAn organic molecular entity containing a single carbon atom (C1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 3Homo sapiens (human)IC50 (µMol)2,200.00000.09003.72779.5000AID1463538
Solute carrier family 22 member 3Homo sapiens (human)Ki6,201.00000.12000.12000.1200AID681584
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)IC50 (µMol)4,470.00000.18003.68578.8000AID681159
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Ki724.20000.13002.37856.9000AID681574
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)IC50 (µMol)171.00001.00004.446710.0000AID681158
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)Ki496.80000.39002.32959.4000AID679638; AID681590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Km1,660.00000.27005.695010.0000AID679822
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)Km451.00009.40009.40009.4000AID678807; AID681589
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
histamine metabolic processSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
monoatomic ion transportSolute carrier family 22 member 3Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin transportSolute carrier family 22 member 3Homo sapiens (human)
organic cation transportSolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 3Homo sapiens (human)
organic anion transportSolute carrier family 22 member 3Homo sapiens (human)
monocarboxylic acid transportSolute carrier family 22 member 3Homo sapiens (human)
monoamine transportSolute carrier family 22 member 3Homo sapiens (human)
spermidine transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine transportSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
regulation of appetiteSolute carrier family 22 member 3Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 3Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 3Homo sapiens (human)
histamine transportSolute carrier family 22 member 3Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 3Homo sapiens (human)
histamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
epinephrine uptakeSolute carrier family 22 member 3Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 3Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 3Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
protein bindingSolute carrier family 22 member 3Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
nuclear outer membraneSolute carrier family 22 member 3Homo sapiens (human)
plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
endomembrane systemSolute carrier family 22 member 3Homo sapiens (human)
membraneSolute carrier family 22 member 3Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 3Homo sapiens (human)
mitochondrial membraneSolute carrier family 22 member 3Homo sapiens (human)
neuronal cell bodySolute carrier family 22 member 3Homo sapiens (human)
presynapseSolute carrier family 22 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (59)

Assay IDTitleYearJournalArticle
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID680958TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Guanidine: 5000 uM) in OCT3-expressing HRPE cells2000American journal of physiology. Renal physiology, Sep, Volume: 279, Issue:3
Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.
AID1589640Selectivity index, ratio of CC50 for human RD cells to EC50 for Enterovirus D68 US/KY/14-18953 infected in human RD cells2019Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8
Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68).
AID1135359Ionization constant, pKa of the compound1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Cyanoguanidine-thiourea equivalence in the development of the histamine H2-receptor antagonist, cimetidine.
AID680325TP_TRANSPORTER: uptake in OCT3-expressing HeLa cells1998The Journal of biological chemistry, Jun-26, Volume: 273, Issue:26
Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta.
AID681169TP_TRANSPORTER: uptake in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID678807TP_TRANSPORTER: uptake in OCT2-expressing HEK293 cells1999Molecular pharmacology, Jul, Volume: 56, Issue:1
Selective substrates for non-neuronal monoamine transporters.
AID199699Antirhinovirus activity against rhinovirus serotype 14 which were grown on Ohio HeLa cells1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity.
AID681054TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.05 uM, Guanidine: 5 uM) in Xenopus laevis oocytes2001Molecular pharmacology, May, Volume: 59, Issue:5
Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney.
AID682100TP_TRANSPORTER: inhibition of TEA uptake (TEA: 60 uM, Guanidine: 5000 uM) in Xenopus laevis oocytes1999The Journal of pharmacology and experimental therapeutics, May, Volume: 289, Issue:2
Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations.
AID199704Antirhinovirus activity against rhinovirus serotype 41 which were grown on Ohio HeLa cells1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity.
AID345041Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.
AID217429Cytotoxicity on the vero cell culture infected with mL and was determined as reduction in protein content by the Lowry test1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
Synthesis and antiviral activity of some N-benzenesulphonylbenzimidazoles.
AID1589639Cytotoxicity against human RD cells after 3 days by neutral red dye-based photometric method2019Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8
Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68).
AID199708Antirhinovirus activity against rhinovirus serotype 85 which were grown on Ohio HeLa cells1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity.
AID217426Cytotoxicity on the vero cell culture infected with mL and was determined as reduction in protein content by the Lowry test1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
Synthesis and antiviral activity of some N-benzenesulphonylbenzimidazoles.
AID681159TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID217581Concentration of compound required to reduce by 50% the number of polio virus plaques in vero cells1992Journal of medicinal chemistry, Mar-06, Volume: 35, Issue:5
Pyrazole-related nucleosides. Synthesis and antiviral/antitumor activity of some substituted pyrazole and pyrazolo[4,3-d]-1,2,3-triazin-4-one nucleosides.
AID679205TP_TRANSPORTER: inhibition of TEA uptake (TEA: 500 uM, Guanidine: 5000 uM) in OCT1A expressing Xenopus laevis oocytes1997The Journal of biological chemistry, Jun-27, Volume: 272, Issue:26
Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A).
AID199710Antirhinovirus activity against rhinovirus serotype 9 which were grown on Ohio HeLa cells1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity.
AID217415Cytotoxicity on the vero cell culture infected with Coxsackie B5 virus at a concentration of 3 ug/mL was determined as cell viability by the MTT test1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
Synthesis and antiviral activity of some N-benzenesulphonylbenzimidazoles.
AID678793TP_TRANSPORTER: uptake in OCT2A-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID681701TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Guanidine: 2500 uM) in OCTN2-expressing HRPE cells1999The Journal of pharmacology and experimental therapeutics, Sep, Volume: 290, Issue:3
Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID54678Antiviral activity against the Coxsackie B5 virus (RNA virus) at a concentration of 80 ug/mL was determined as total cell infectious dose 50/mL (TCID50) by viral yield assay1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
Synthesis and antiviral activity of some N-benzenesulphonylbenzimidazoles.
AID681990TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Guanidine: 1000 uM) in OCT2-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID217418Cytotoxicity on the vero cell culture infected with Coxsackie B5 virus at a concentration of 80 ug/mL was determined as cell viability by the MTT test1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
Synthesis and antiviral activity of some N-benzenesulphonylbenzimidazoles.
AID26079pKa was determined2001Bioorganic & medicinal chemistry letters, Mar-12, Volume: 11, Issue:5
The synthesis of beta-peptides containing guanidino groups.
AID199706Antirhinovirus activity against rhinovirus serotype 63 which were grown on Ohio HeLa cells1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity.
AID681584TP_TRANSPORTER: inhibition of MPP+ uptake in OCT3-expressing HRPE cells2000American journal of physiology. Renal physiology, Sep, Volume: 279, Issue:3
Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.
AID1463538Inhibition of OCT3 (unknown origin)2017Bioorganic & medicinal chemistry letters, 09-15, Volume: 27, Issue:18
A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3).
AID679638TP_TRANSPORTER: inhibition of MPP+ uptake in OCT2-expressing HEK293 cells1999Molecular pharmacology, Jul, Volume: 56, Issue:1
Selective substrates for non-neuronal monoamine transporters.
AID15565Distribution in dog adrenal medulla 30 min after administration.1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines.
AID1589638Antiviral activity against Enterovirus D68 US/KY/14-18953 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect incubated for 5 mins under shaking condition and measured after 3 days by neutral red dye-based photometric meth2019Journal of medicinal chemistry, 04-25, Volume: 62, Issue:8
Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68).
AID681590TP_TRANSPORTER: inhibition of TEA uptake (basolateral to cell) in OCT2-expressing MDCK cells1998The Journal of pharmacology and experimental therapeutics, Nov, Volume: 287, Issue:2
Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs.
AID199705Antirhinovirus activity against rhinovirus serotype 59 which were grown on Ohio HeLa cells1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity.
AID199701Antirhinovirus activity against rhinovirus serotype 2 which were grown on Ohio HeLa cells1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity.
AID54675Antiviral activity against the Coxsackie B5 virus (RNA virus) at a concentration of 3 ug/mL was determined as total cell infectious dose 50/mL (TCID50) by viral yield assay1999Bioorganic & medicinal chemistry letters, Sep-06, Volume: 9, Issue:17
Synthesis and antiviral activity of some N-benzenesulphonylbenzimidazoles.
AID681989TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, Guanidine: 1000 uM) in OCT2A-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID199707Antirhinovirus activity against rhinovirus serotype 70 which were grown on Ohio HeLa cells1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID680540TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.01 uM, Guanidine: 500 uM) in OCTN2-expressing HEK293 cells2001Molecular pharmacology, Feb, Volume: 59, Issue:2
Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2.
AID682268TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM, Guanidine: 5000 uM) in OCTN2-expressing HeLa cells1998Biochemical and biophysical research communications, May-29, Volume: 246, Issue:3
cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family.
AID199702Antirhinovirus activity against rhinovirus serotype 29 which were grown on Ohio HeLa cells1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity.
AID681158TP_TRANSPORTER: inhibition of TEA uptake (TEA: 10 uM) in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID26313pKa value determined2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
Solution-phase, parallel synthesis and pharmacological evaluation of acylguanidine derivatives as potential sodium channel blockers.
AID679169TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000American journal of physiology. Renal physiology, Sep, Volume: 279, Issue:3
Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney.
AID681574TP_TRANSPORTER: inhibition of TEA uptake (basolateral to cell) in OCT1-expressing MDCK cells1998The Journal of pharmacology and experimental therapeutics, Nov, Volume: 287, Issue:2
Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID681589TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID199700Antirhinovirus activity against rhinovirus serotype 15 which were grown on Ohio HeLa cells1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity.
AID199709Antirhinovirus activity against rhinovirus serotype 89 which were grown on Ohio HeLa cells1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity.
AID199703Antirhinovirus activity against rhinovirus serotype 39 which were grown on Ohio HeLa cells1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
4'-Hydroxy-3-methoxyflavones with potent antipicornavirus activity.
AID682308TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, Guanidine: 500 uM) in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID679822TP_TRANSPORTER: uptake in Xenopus laevis oocytes2001American journal of physiology. Renal physiology, Sep, Volume: 281, Issue:3
Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1.
AID15566Distribution in dog adrenal medulla 72 hours after administration.1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines.
AID230956Ratio of the concentration levels determined for the adrenal medulla to the liver after 72 hr; [Adrenal Medulla] / [liver]1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines.
AID679158TP_TRANSPORTER: uptake in OCT2-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID682218TP_TRANSPORTER: uptake in Xenopus laevis oocytes1998The Journal of biological chemistry, Jun-26, Volume: 273, Issue:26
Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5,415)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990881 (16.27)18.7374
1990's1337 (24.69)18.2507
2000's1767 (32.63)29.6817
2010's1140 (21.05)24.3611
2020's290 (5.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.69 (24.57)
Research Supply Index8.62 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index121.23 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (67.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (0.07%)5.53%
Reviews93 (1.67%)6.00%
Case Studies10 (0.18%)4.05%
Observational0 (0.00%)0.25%
Other5,448 (98.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]